Zansecimab: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 95 patientsc19early.org

Zansecimab for COVID-19

Serious outcome risk
Zansecimab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−36%
Mortality (1)−36%
RCTs (1)−36%
Late (1)−36%
00.511.5+
← Zansecimab
reduces riskIncreased
risk →
c19early.org
October 2026

Zansecimab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jones (DB RCT)−36%1.36 · 0.51–3.63death8/476/48
Late treatment−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.55
All studies−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zansecimab
reduces riskZansecimab
increases risk →
c19early.org
October 2026

Zansecimab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Jones (DB RCT)−36%1.36 · 0.51–3.638/476/48
Late treatment−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.55
All studies−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zansecimab
reduces riskZansecimab
increases risk →
c19early.org
October 2026

Zansecimab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jones (DB RCT)−36%1.36 · 0.51–3.63death8/476/48
Late treatment−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.55
All studies−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zansecimab
reduces riskZansecimab
increases risk →
c19early.org
October 2026

Zansecimab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jones (DB RCT)−36%1.36 · 0.51–3.63death8/476/48
Late treatment−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.55
All studies−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zansecimab
reduces riskZansecimab
increases risk →
c19early.org
October 2026

Zansecimab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Jones (DB RCT)−36%1.36 · 0.51–3.638/476/48
Late treatment−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.55
All studies−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zansecimab
reduces riskZansecimab
increases risk →
c19early.org
October 2026

Zansecimab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jones (DB RCT)−36%1.36 · 0.51–3.63death8/476/48
Late treatment−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.55
All studies−36%1.36 · 0.51–3.638/476/4836% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zansecimab
reduces riskZansecimab
increases risk →